Amgen R&D chief Sean Harper hits the exits with a one-way ticket to early-stage biotech
Sean Harper is joining the migration out of big biopharma and into the world of emerging biotechs.
The head of R&D at Amgen has turned in his notice, 6 years after taking the senior R&D position vacated by Roger Perlmutter.
We don’t know right now where he’s headed, but in a statement Amgen said that the 55-year-old is leaving Amgen and “plans to pursue opportunities in the early-stage biotechnology community.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.